JSJason Shumake

Jason Shumake

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jason Shumake has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Investigating the role of affective valence and arousal in exposure therapy for anxiety and related disorders

    by Hayley E. Fitzgerald, Laura J. Long, Star Moore, Adam R. Cobb, Rebecca E. Lubin, E. Marie Parsons, Nadine R. Taghian, Jason Shumake, Marie-H. Monfils, Michael J. Telch, et al.

    Anxiety and related disorders are highly prevalent (Baxter et al., 2012) and associated with significant distress and disability (Bandelow & Michaelis, 2015; Olatunji et al., 2007). Fortunately, in...

  • Complex Emotion Dynamics Contribute to the Prediction of Depression: A Machine Learning and Time Series Feature Extraction Approach

    by Mackenzie Zisser, Jason Shumake, Christopher G. Beevers

    Emotion dynamics have demonstrated mixed ability to predict depressive symptoms and outperform traditional metrics like the mean and standard deviation of emotion reports. Here, we expand the types of emotion dynamic features used in prior work and apply a machine learning algorithm to predict depression symptoms. We obtained seven ecological momentary assessment (EMA) studies from previous work on depression and emotion dynamics (N = 890). These studies measured self-reported sadness, positive affect, and negative affect 5 to 10 times per day for 7 to 21 days (schedule varied across studies). These data were fed through a feature extraction routine to generate hundreds of emotion dynamic features. A gradient boosting machine (GBM) using all available emotion dynamics features was the best of all models assessed. This model’s out-of-sample prediction (R2pred) for depression severity ranged from .20 to .44 depending on EMA interpolation method and samples included in the analysis. It also explained significantly more variance than a benchmark model of individuals’ mean emotion ratings over the assessment period, R2pred = .089. Comprehensive feature mining of emotion dynamics obtained during EMA may be necessary to identify processes that predict depression symptoms beyond mean emotion ratings.


  • Open Access

    Web-Based Single Session Intervention for Perceived Control Over Anxiety During COVID-19: Randomized Controlled Trial

    by Michael Mullarkey, Mallory Dobias, Jenna Sung, Isaac Ahuvia, Jason Shumake, Christopher Beevers, Jessica Schleider

    Background: Anxiety is rising across the United States during the COVID-19 pandemic, and social distancing mandates preclude in-person mental health care. Greater perceived control over anxiety has predicted decreased anxiety pathology, including adaptive responses to uncontrollable stressors. Evidence suggests that no-therapist, single-session interventions can strengthen perceived control over emotions like anxiety; similar programs, if designed for the COVID-19 context, could hold substantial public health value.Objective: Our registered report evaluated a no-therapist, single-session, online intervention targeting perceived control over anxiety in the COVID-19 context against a placebo intervention encouraging handwashing. We tested whether the intervention could (1) decrease generalized anxiety and increase perceived control over anxiety and (2) achieve this without decreasing social-distancing intentions.Methods: We tested these questions using a between-subjects design in a weighted-probability sample of US adults recruited via a closed online platform (ie, Prolific). All outcomes were indexed via online self-report questionnaires.Results: Of 522 randomized individuals, 500 (95.8%) completed the baseline survey and intervention. Intent-to-treat analyses using all randomized participants (N=522) found no support for therapeutic or iatrogenic effects; effects on generalized anxiety were d=–0.06 (95% CI –0.27 to 0.15; P=.48), effects on perceived control were d=0.04 (95% CI –0.08 to 0.16; P=.48), and effects on social-distancing intentions were d=–0.02 (95% CI –0.23 to 0.19; P=.83).Conclusions: Strengths of this study included a large, nationally representative sample and adherence to open science practices. Implications for scalable interventions, including the challenge of targeting perceived control over anxiety, are discussed.Trial Registration: ClinicalTrials.gov NCT04459455; https://clinicaltrials.gov/show/NCT04459455


  • Change in negative attention bias mediates the association between attention bias modification training and depression symptom improvement.

    by Christopher G. Beevers, Kean J. Hsu, David M. Schnyer, Jasper A. J. Smits, Jason Shumake

    Attention bias modification training (ABMT) is purported to reduce depression by targeting and modifying an attentional bias for sadness-related stimuli. However, few tests of this hypothesis have been completed. The current study examined whether change in attentional bias mediated a previously reported association between ABMT condition (active ABMT, sham ABMT, assessments only; N = 145) and depression symptom change among depressed adults. The pre-registered, primary measure of attention bias was a discretized eye tracking metric that quantified the proportion of trials where gaze time was greater for sad stimuli than neutral stimuli. Contemporaneous longitudinal simplex mediation indicated that change in attentional bias early in treatment partially mediated the effect of ABMT on depression symptoms. Specificity analyses indicated that in contrast to the eye-tracking mediator, reaction time assessments of attentional bias for sad stimuli (mean bias and trial level variability) and lapses in sustained attention did not mediate the association between ABMT and depression change. Results also suggested that mediation effects were limited to a degree by suboptimal measurement of attentional bias for sad stimuli. When effective, ABMT may improve depression in part by reducing an attentional bias for sad stimuli, particularly early on during ABMT. Prior work has shown that ABMT reduces depression but it is unclear why this is so. The current study confirms that ABMT works by reducing a tendency to focus attention on negative information, which in turn reduces symptoms of depression.


  • Open Access

    Web-Based Single Session Intervention for Perceived Control Over Anxiety During COVID-19: Randomized Controlled Trial (Preprint)

    by Michael Mullarkey, Mallory Dobias, Jenna Sung, Isaac Ahuvia, Jason Shumake, Christopher Beevers, Jessica Schleider

    BACKGROUND Anxiety is rising across the United States during the COVID-19 pandemic, and social distancing mandates preclude in-person mental health care. Greater perceived control over anxiety has predicted decreased anxiety pathology, including adaptive responses to uncontrollable stressors. Evidence suggests that no-therapist, single-session interventions can strengthen perceived control over emotions like anxiety; similar programs, if designed for the COVID-19 context, could hold substantial public health value. OBJECTIVE Our registered report evaluated a no-therapist, single-session, online intervention targeting perceived control over anxiety in the COVID-19 context against a placebo intervention encouraging handwashing. We tested whether the intervention could (1) decrease generalized anxiety and increase perceived control over anxiety and (2) achieve this without decreasing social-distancing intentions. METHODS We tested these questions using a between-subjects design in a weighted-probability sample of US adults recruited via a closed online platform (ie, Prolific). All outcomes were indexed via online self-report questionnaires. RESULTS Of 522 randomized individuals, 500 (95.8%) completed the baseline survey and intervention. Intent-to-treat analyses using all randomized participants (N=522) found no support for therapeutic or iatrogenic effects; effects on generalized anxiety were d=–0.06 (95% CI –0.27 to 0.15; P=.48), effects on perceived control were d=0.04 (95% CI –0.08 to 0.16; P=.48), and effects on social-distancing intentions were d=–0.02 (95% CI –0.23 to 0.19; P=.83). CONCLUSIONS Strengths of this study included a large, nationally representative sample and adherence to open science practices. Implications for scalable interventions, including the challenge of targeting perceived control over anxiety, are discussed. CLINICALTRIAL ClinicalTrials.gov NCT04459455; https://clinicaltrials.gov/show/NCT04459455

  • Multifactorial prediction of depression diagnosis and symptom dimensions

    by Mary E. McNamara, Jason Shumake, Rochelle A. Stewart, Jocelyn Labrada, Alexandra Alario, John J.B. Allen, Rohan Palmer, David M. Schnyer, John E. McGeary, Christopher G. Beevers


  • Open Access

    Inclusion of genetic variants in an ensemble of gradient boosting decision trees does not improve the prediction of citalopram treatment response

    by Jason Shumake, Travis T. Mallard, John E. McGeary, Christopher G. Beevers

    Identifying in advance who is unlikely to respond to a specific antidepressant treatment is crucial to precision medicine efforts. The current work leverages genome-wide genetic variation and machine learning to predict response to the antidepressant citalopram using data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (n = 1257 with both valid genomic and outcome data). A confirmatory approach selected 11 SNPs previously reported to predict response to escitalopram in a sample different from the current study. A novel exploratory approach selected SNPs from across the genome using nested cross-validation with elastic net logistic regression with a predominantly lasso penalty (alpha = 0.99). SNPs from each approach were combined with baseline clinical predictors and treatment response outcomes were predicted using a stacked ensemble of gradient boosting decision trees. Using pre-treatment clinical and symptom predictors only, out-of-fold prediction of a novel treatment response definition based on STAR*D treatment guidelines was acceptable, AUC = .659, 95% CI [0.629, 0.689]. The inclusion of SNPs using confirmatory or exploratory selection methods did not improve the out-of-fold prediction of treatment response (AUCs were .662, 95% CI [0.632, 0.692] and .655, 95% CI [0.625, 0.685], respectively). A similar pattern of results were observed for the secondary outcomes of the presence or absence of distressing side effects regardless of treatment response and achieving remission or satisfactory partial response, assuming medication tolerance. In the current study, incorporating SNP variation into prognostic models did not enhance the prediction of citalopram response in the STAR*D sample.


  • Open Access

    Response: Commentary: Acetaminophen Enhances the Reflective Learning Process

    by Jason Shumake, Rahel Pearson, Seth Koslov, Bethany Hamilton, Charles S. Carver, Christopher G. Beevers

    Response: Commentary: Acetaminophen Enhances the Reflective Learning Process